Literature DB >> 18072597

Long-term storage of DNA-free RNA for use in vaccine studies.

Kathryn L Jones1, Debbie Drane, Eric J Gowans.   

Abstract

RNA replicons represent potential vaccine delivery vehicles, but are considered too unstable for such use. This study examined the recovery, integrity and function of in vitro transcribed replicon RNA encoding hepatitis C virus (HCV) proteins. To remove residual template DNA, the RNA was digested with TURBO DNase followed by RNeasy DNase set and purified through an RNeasy column. The RNA was freeze-dried in distilled water or trehalose, stored under nitrogen gas for up to 10 months and analyzed at different time points. The recovery of RNA stored at < or = 4 degrees C that was freeze-dried in distilled water varied between 66% to zero of that recovered from RNA freeze-dried in 10% trehalose, a figure that depended on the duration of storage. In contrast, the recovery of the RNA stored in trehalose was consistently high for all time points. After recovery, both RNAs were translationally competent and expressed high levels of proteins after transfection, although the level of expression from the trehalose-stored RNA was consistently higher. Thus the addition of trehalose permitted stable storage of functional RNA at 4 degrees C for up to 10 months and this permits the development of RNA vaccines, even in developing countries where only minimum storage conditions (e.g., 4 degrees C) can be achieved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072597      PMCID: PMC4526277          DOI: 10.2144/000112593

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  30 in total

1.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Intracellular trehalose improves the survival of cryopreserved mammalian cells.

Authors:  A Eroglu; M J Russo; R Bieganski; A Fowler; S Cheley; H Bayley; M Toner
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

Review 3.  Anhydrobiosis.

Authors:  J H Crowe; F A Hoekstra; L M Crowe
Journal:  Annu Rev Physiol       Date:  1992       Impact factor: 19.318

4.  Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.

Authors:  Jon A Kyte; Gunnar Kvalheim; Steinar Aamdal; Stein Saebøe-Larssen; Gustav Gaudernack
Journal:  Cancer Gene Ther       Date:  2005-06       Impact factor: 5.987

5.  In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model.

Authors:  C W Mandl; J H Aberle; S W Aberle; H Holzmann; S L Allison; F X Heinz
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

6.  Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA.

Authors:  P Carninci; Y Nishiyama; A Westover; M Itoh; S Nagaoka; N Sasaki; Y Okazaki; M Muramatsu; Y Hayashizaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

7.  Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.

Authors:  Marco Vignuzzi; Sylvie Gerbaud; Sylvie van der Werf; Nicolas Escriou
Journal:  J Gen Virol       Date:  2001-07       Impact factor: 3.891

8.  Development of animal recombinant DNA vaccine and its efficacy in foxes.

Authors:  M P Kieny; J Blancou; R Lathe; P P Pastoret; J P Soulebot; P Desmettre; J P Lecocq
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

9.  A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

Authors:  L J Mu; G Gaudernack; S Saebøe-Larssen; H Hammerstad; A Tierens; G Kvalheim
Journal:  Scand J Immunol       Date:  2003-11       Impact factor: 3.487

10.  Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Authors:  Matthew F Kalady; Mark W Onaitis; Karen M Padilla; Sirisha Emani; Douglas S Tyler; Scott K Pruitt
Journal:  J Surg Res       Date:  2002-06-01       Impact factor: 2.192

View more
  30 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

2.  Nonviral delivery of self-amplifying RNA vaccines.

Authors:  Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

Review 3.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

4.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 5.  Messenger RNA (mRNA) nanoparticle tumour vaccination.

Authors:  Kyle K L Phua; Smita K Nair; Kam W Leong
Journal:  Nanoscale       Date:  2014-07-21       Impact factor: 7.790

Review 6.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

Review 7.  A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.

Authors:  Ahmad M Aldossary; Chinedu S M Ekweremadu; Ifunanya M Offe; Haya A Alfassam; Sooyeon Han; Vivian C Onyali; Chukwuebuka H Ozoude; Emmanuel A Ayeni; Chinekwu S Nwagwu; Abdulrahman A Halwani; Nada H Almozain; Essam A Tawfik
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

8.  Capillary-Mediated Vitrification: Preservation of mRNA at Elevated Temperatures.

Authors:  Sankar Renu; Mary Shank-Retzlaff; Jenny Sharpe; Laura Bronsart; Pravansu Mohanty
Journal:  AAPS J       Date:  2022-06-16       Impact factor: 3.603

Review 9.  RNA therapeutics for cardiovascular disease.

Authors:  Christian Boada; Roman Sukhovershin; Roderic Pettigrew; John P Cooke
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

Review 10.  Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.

Authors:  Javier T Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  Biomed Pharmacother       Date:  2021-07-23       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.